Used as an intermediate in the synthesis of dabigatran etexilate, a potent oral anticoagulant prodrug. It plays a key role in pharmaceutical development for producing the drug substance used in the treatment and prevention of thromboembolic disorders, such as stroke in patients with non-valvular atrial fibrillation. Dabigatran etexilate is metabolized in the body to the active form, dabigatran, a direct thrombin inhibitor that enhances bioavailability and reduces clotting risk.